...'Elsa' will help employees “work more efficiently.”

It should come as no surprise then, that big pharma and the medical establishment have absolutely no interest in pursuing low-cost treatments, especially when it comes to diseases such as cancer that are a cash cow for big pharma.

An official with a documented role in the Internal Revenue Service’s targeting of conservative groups during the Obama administration is now serving as